General information
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein, Rhineland-Palatinate
Germany
Contact person: Harro Ten Wolde, Head of Global Media Relations
Company main phone: +49 (6132) 770
Company main fax: +49 (6132) 720
Website: https://www.boehringer-ingelheim.com
Year founded: | 1885
|
Source of foundation: | Independent foundation |
Name of foundation source: | Founded by Mr. Albert Boehringer |
No. of employees: |
Worldwide: 53500 |
Corporate description / mission:
Boehringer Ingelheim International GmbH researches, develops, manufactures and markets human and veterinary pharmaceutical products. The company's product Aptivus® indicated for combination antiretroviral treatment of HIV-1-infected patients, co-administered with 200 mg of ritonavir, who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor. The company's another product Atrovent® is used for the prevention and treatment of shortness of breath in patients with chronic obstructive pulmonary disease (COPD) and mild to moderate bronchial asthma in adulthood and childhood as a supplement to beta-agonists in cases of acute asthma.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector: |
- Pharma (fully integrated)
|
Subsector: |
- Anti-infectives
- Antibodies
- Nucleic acid drugs
- Peptides
- Proteins
- Vaccines
|
Primary therapeutic areas: |
- Cardiovascular / cardiology
- Digestive system / gastroenterology
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the eye / ophthalmology
- Diseases of the nervous system / neurology
- Endocrine, nutritional and metabolic diseases / endocrinology
- External causes of morbidity and mortality / traumatology
- Genitourinary system / Urology
- Infectious and parasitic diseases / infectiology / parasitology
- Mental and behavioural disorders / psychiatry /psychology
- Musculoskeletal system and connective tissue / Orthopedics
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Business model: |
- In-licensing
- Manufacturer
- Out-licensing
- R&D
- Supplier / Distributor
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
- Physicians / doctors
- Small biotech
|
Distribution: |
- Direct (own sales force)
- Indirect (independent dealer)
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 24 | |
Phase I: | 36 | |
Phase II: | 24 | |
Phase III: | 14 | |
On the market: | 15 | |
Description of products:
Survodutide
Spesolimab, etc.
Collaborations & Clients
Partnering strategy / collaborations:
Institute of Molecular Pathology (IMP)
Institute of Molecular Biology (IMB)
University of Applied Sciences in Biberach, Germany
University of Ulm, Germany
Technische Universität Dresden, etc.